When Burton-on-Trent based pharmaceutical company Clinigen was floated on the AIM market it was hailed as one of the best stock market launches of the year.
And the £135 million flotation in September 2012 also meant a windfall for Andrew and Linda Leaver who sold shares worth £37 million. They retained a £47 million stake in the group which Andrew Leaver, 51, formed in 2010, bringing together Keats Healthcare, Clinigen GAP and Clinigen SP.
The company was set up to supply medicines for clinical trials. It quickly developed into a global provider of specialist pharmaceutical products and services and in 2011 was hailed as the fastest growing private company in the UK in the Sunday Times Fast Track 100. The company is currently trialling a drug designed to counteract the effects of MRSA-related infections. The drug has the potential to make a huge difference to critically-ill patients.
Now it has outlets in Tokyo and Philadelphia, as well as its headquarters and a distribution centre in Burton. The company supplies more than 50 countries around the world, with a fast growing customer base of pharmaceutical companies, biotechnology specialists and research organisations.
Keats Healthcare has been rebranded as Clinigen CTS, dedicated to sourcing and supplying commercial medicines for clinical study. Clinigen GAP provides pharmaceutical consultancy and development while Clinigen SP concentrates on specialist pharmaceuticals and hospital-only medicines worldwide, commercialising them in niche markets.
CSR is on the company’s agenda and Clinigen sponsored Leek-born rower Anna Watkins who took Olympic gold in the double sculls.
The City was impressed with the Clinigen IPO. The deal won IPO of the Year at last year’s M&A Awards, and the firm won the Best Newcomer accolade at the London Stock Exchange AIM Awards.